TEL AVIV, Israel, April 6, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.
| 10th Annual Neurotech Investing & Partnering Conference | ||
| Date: | Tuesday, April 7 | |
| Time: | 3:30pm Pacific Time | |
| Location: | Hotel Nikko, San Francisco | |
| Presenter: | David Baker, Chief Commercial Officer | |
| Conference Information: | www.neurotechconf.com | |
| Neurology Innovation Conference | ||
| Date: | Sunday, April 19 | |
| Time: | 3:30pm Eastern Time | |
| Location: | Embassy Suites, Washington DC | |
| Presenter: | Jonathan Rubin, MD, MBA, Chief Medical Officer | |
| Conference Information: | www.neurologyinnovation.com | |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.